Pioglitazone for Lung Cancer Chemoprevention

Summary

This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either placebo or pioglitazone and have chest computerized tomography (CAT) scans and examinations of their airways with a bronchoscope at the start of the trial and after 6 months on treatment. Compensation will be provided to the subject after completing the trial.

Timeline

Start

2009-08

Primary completion

2016-06

Completion

2017-08

Outcome

Missed primary endpoint

registry analysis (other test); Arm 1: Pioglitazone vs Arm 2: Placebo; p = 0.53; Regression model parameter (α1) -0.40 (95% CI -1.68 to 0.89); Regression, Linear NCT00780234 ↗

Drugs

Indications